

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HIGHLY SPECIALISED TECHNOLOGY EVALUATION PROGRAMME

Equality impact assessment – Guidance development

HST: Eculizumab for treating atypical haemolytic uraemic syndrome

The impact on equality has been assessed during this evaluation according to the principles of the NICE equality scheme.

Consultation

- | |
|---|
| 1. Have the potential equality issues identified during the scoping process been addressed by the Committee, and, if so, how? |
|---|

No specific equality issues were raised during the scoping process. The Committee has considered the health needs of all patients included in the population in the scope during the course of the evaluation to date.
--

- | |
|--|
| 2. Have any other potential equality issues been raised in the submissions, expert statements or independent academic report, and, if so, how has the Committee addressed these? |
|--|

No specific equality issues were raised in the submissions from consultees, expert statements or in the evidence review group's independent academic report. One consultee however noted that age is a protected characteristic and that if different recommendations were made for children and adults, this could lead to inequality. Different recommendations were not made for children and adults and so there was no need to address this potential equality issue.
--

- | |
|--|
| 3. Have any other potential equality issues been identified by the Committee, and, if so, how has the Committee addressed these? |
|--|

No equality issues were identified by Committee.
--

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No

5. Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No

6. Are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

Not applicable.

7. Have the Committee's considerations of equality issues been described in the evaluation consultation document, and, if so, where?

The summary table at the end of the evaluation consultation document states that no equality issues were raised during the scoping process or during the course of the evaluation but notes that a consultee was concerned that inequality could be introduced if different recommendations on the use of eculizumab are made for children and adults.

Approved by Associate Director (name): Josie Godfrey

Date: 2 September 2014

Final evaluation determination

(when an ECD issued)

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the Committee addressed these?

A patient organisation stated that although the recommendations do not exclude anyone from receiving rescue therapy with eculizumab if needed, there is a concern for people who risk disease recurrence through pregnancy. The Committee heard from the patient expert that more research should be conducted on the use of eculizumab before or during pregnancy and the Committee supported this. The Committee concluded that because its recommendations do not restrict access to eculizumab during pregnancy, there was no need to alter them.

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

Not applicable

3. If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

Not applicable

4. If the recommendations have changed after consultation, are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?

Not applicable

5. Have the Committee's considerations of equality issues been described in the final evaluation determination, and, if so, where?

Yes, the Committee's considerations of equality issues have been described in section 5.21 and in the summary table in the final evaluation determination.

Approved by Centre or Programme Director (name): Meindert Boysen

Date: 22 January 2015